If you or someone you know has taken Elmiron (pentosan polysulfate sodium) long-term for interstitial cystitis, you may have heard about potential eye symptoms. The medical community has increasingly recognized that chronic use of this medication can be linked to a distinct form of pigmentary maculopathy. This page provides a clear, factual overview of the prescribing information checklist for Elmiron eye symptoms, helping you understand what is known and what steps to consider.
Elmiron (pentosan polysulfate sodium) is a medication approved for the treatment of interstitial cystitis, a chronic bladder condition. Long-term use of Elmiron has been associated with the development of pigmentary maculopathy, a condition characterized by pigmentary changes in the retina that can lead to visual symptoms. The U.S. Food and Drug Administration (FDA) label for Elmiron includes a warning about this risk, noting that pigmentary changes in the retina have been identified with long-term use, with most cases occurring after three years or more, though cases have been seen with shorter durations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The label states that cumulative dose appears to be a risk factor, and visual symptoms reported include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The clinical presentation of pigmentary maculopathy involves pigmentary changes in the retina, which can be detected through ophthalmologic examination. The FDA label recommends that a detailed ophthalmologic history be obtained in all patients before starting Elmiron, and for those with pre-existing conditions, a comprehensive baseline retinal examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging, is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For all patients, a baseline retinal examination, including OCT and auto-fluorescence imaging, is suggested within six months of initiating treatment and periodically thereafter (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). If pigmentary changes develop, the risks and benefits of continuing treatment should be re-evaluated, as these changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The mechanistic pathways linking Elmiron to pigmentary maculopathy are not fully understood, but the FDA label indicates that the etiology is unclear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Research has examined the association between pentosan polysulfate sodium (PPS), the active ingredient in Elmiron, and the development of pigmentary maculopathy in patients with interstitial cystitis. A single-center retrospective study at Wake Forest School of Medicine evaluated patients with interstitial cystitis who had at least two eye examinations between January 2011 and August 2021, using multimodal imaging and established criteria to assess for pigmentary maculopathy (https://pubmed.ncbi.nlm.nih.gov/41049115/). The study analyzed associations between pigmentary maculopathy and PPS exposure duration and cumulative dose, as well as concurrent interstitial cystitis medication use (https://pubmed.ncbi.nlm.nih.gov/41049115/). This research supports the link between Elmiron use and retinal pigmentary changes. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) provide additional evidence of the association. The most frequently reported adverse events associated with Elmiron include maculopathy (1,382 reports), retinal pigmentation (607 reports), and pigmentary maculopathy (442 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other reported events include dry age-related macular degeneration, macular degeneration, and visual impairment (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). These reports highlight the significant number of patients who have experienced retinal issues potentially linked to Elmiron.
The adequacy of warnings regarding Elmiron and pigmentary maculopathy is a key consideration. The FDA label includes a warning about retinal pigmentary changes and provides recommendations for monitoring, but the label also notes that the visual consequences of these changes are not fully characterized (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For patients who developed pigmentary maculopathy after using Elmiron, questions may arise about whether the warnings were sufficient to inform them of the risk, especially given that the condition can be irreversible. For affected patients, attorney-related considerations include the timeline between exposure and documented harm. The FDA label indicates that most cases of pigmentary maculopathy occurred after three years or more of use, but cases have been seen with shorter durations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). This timeline is important for legal claims, as it may affect the ability to establish a causal link between Elmiron use and the development of pigmentary maculopathy. Patients who have experienced visual symptoms such as difficulty reading, slow adjustment to low light, or blurred vision after long-term Elmiron use may consider consulting with an attorney to discuss potential legal options. Settlement criteria for Elmiron pigmentary maculopathy lawsuits typically involve factors such as the duration and cumulative dose of Elmiron use, the presence of documented pigmentary changes on retinal imaging, and the severity of visual symptoms. Patients should have medical records that include ophthalmologic examinations, such as OCT and auto-fluorescence imaging, to support their claims. The FDA label's recommendation for baseline and periodic retinal examinations underscores the importance of monitoring for these changes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Elmiron (pentosan polysulfate sodium) is a medication used to treat interstitial cystitis. Long-term use has been associated with pigmentary maculopathy, a retinal condition that can cause visual symptoms like difficulty reading and blurred vision. The FDA label includes a warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Settlement criteria typically include the duration and cumulative dose of Elmiron use, documented pigmentary changes on retinal imaging (e.g., OCT), and severity of visual symptoms. Medical records confirming exposure and diagnosis are essential. Consulting an attorney can help assess eligibility.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.